Landec Corporation, together with its subsidiaries, engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of plant-based salads, and fresh-cut and whole processed vegetables primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels to retail grocery chains, club stores, and food service operators; and sells BreatheWay packaging products. The Lifecore segment manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products to treat various medical conditions and procedures. It also provides product development services, including technology transfer, material component changes, analytical method and formulation development, pilot and stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It operates in the United States, Canada, Belgium, Switzerland, Czech Republic, Ireland, and internationally. The company was incorporated in 1986 and is headquartered in Santa Maria, California.
IPO Year: 1996
Exchange: NASDAQ
Website: landec.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $14.00 | Mkt Perform → Outperform | Barrington Research |
| 7/20/2022 | $13.00 | Overweight | Stephens |
| 4/6/2022 | Outperform → Mkt Perform | Barrington Research | |
| 10/4/2021 | $15.00 → $14.00 | Buy | Roth Capital |
| 7/30/2021 | $12.00 → $15.00 | Buy | Roth Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
Fastest customizable press release news feed in the world
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N
CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel
CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f
Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Landec Corp. (NASDAQ:LNDC) (the "Company") announced today that it received a notice ("Notice") on September 2, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") because the Company failed to timely file its Annual Report on Form 10-K for the year ended May 29, 2022 (the "Form 10-K") with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Global Select Market. The Notice states that the Comp
Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes Lifecore segment revenues increased 6.9% to $27.6 million in fiscal fourth quarter, and increased 11.5% to $109.3 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment EBITDA increased 14.5% to $8.8 million in fiscal fourth quarter, and increased 16.4% to $28.5 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment adjusted EBITDA increased 15.9% to $8.9 million in fiscal fourth quarter, and increased 17.9% to $28.9 million for the full fiscal year 2022, as compared to the
Landec expected to rename and rebrand to Lifecore Biomedical and update Nasdaq ticker symbol Names new CEO Announces future changes to its Board of Directors SANTA MARIA, Calif. and MINNEAPOLIS, Minn. , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today formally announced the Company's path fo
SANTA MARIA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2022 fourth quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be ava
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00
Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00
Barrington Research downgraded Landec from Outperform to Mkt Perform
Roth Capital reiterated coverage of Landec with a rating of Buy and set a new price target of $14.00 from $15.00 previously
Roth Capital reiterated coverage of Landec with a rating of Buy and set a new price target of $15.00 from $12.00 previously
Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $13.00
Roth Capital reiterated coverage of Landec with a rating of Buy and set a new price target of $12.00 from $15.00 previously
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
NT 10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
NT 10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
Live Leadership Updates
Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm
Live finance-specific insights
Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web
Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes Lifecore segment revenues increased 6.9% to $27.6 million in fiscal fourth quarter, and increased 11.5% to $109.3 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment EBITDA increased 14.5% to $8.8 million in fiscal fourth quarter, and increased 16.4% to $28.5 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment adjusted EBITDA increased 15.9% to $8.9 million in fiscal fourth quarter, and increased 17.9% to $28.9 million for the full fiscal year 2022, as compared to the
SANTA MARIA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2022 fourth quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be ava
Lifecore segment revenues increased 27.9% in fiscal third quarter, as compared to prior year period Reiterates fiscal 2022 full year guidance SANTA MARIA, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2022 third quarter ended February 27, 2022. As previously reported, on December 13, 2021 the Company closed on the sale of its Curation Food's fresh packaged salads and vegetables business (the "Eat Smart Disposition"), and as such, those results
SANTA MARIA, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – will host a conference call to discuss fiscal 2022 third quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be available for 30 days. Dat
Reiterates Fiscal 2022 Guidance for Lifecore Provides Pro Forma Curation Foods Segment Results and Updates Guidance for Continuing Segment Operations SANTA MARIA, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc., reported results for the fiscal 2022 second quarter ended November 28, 2021. Subsequent to fiscal second quarter end, on December 13, 2021 the Company closed on the sale of its Curation Food's fresh packaged salads and vegetables business (the "Eat Smart Disposition") for $73.5 million in c
SALINAS, Calif., Dec. 14, 2021 /PRNewswire/ -- Taylor Farms announces the acquisition of Curation Foods' fresh packaged salads, green beans and fresh cut vegetables business from Landec Corporation (NASDAQ:LNDC), effective December 13th, 2021. The assets include the Eat Smart® brand and production facilities in Guadalupe, CA and Bowling Green, OH. The addition of Curation Foods' packaged salad and fresh cut vegetables business will help the Taylor Farms Retail Division meet consumers growing demand for chopped salads and fresh cut vegetables. "This acquisition will enhance ou
Strategic sale results in a CDMO-focused company aligned with attractive growth categories and end marketsNet proceeds from the sale will be allocated towards debt pay down, resulting in significant deleveragingAnnounces fiscal second quarter earnings call on January 5, 2022 SANTA MARIA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable ph
This live feed shows all institutional transactions in real time.
SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)